CliffBio
small molecule

DEFERASIROX

DEFERASIROX

Loss of exclusivity—loss of exclusivity
CompanyAUCTA →See this company's full patent-cliff portfolio

Drug detail

Brand nameDEFERASIROX
Active ingredientDEFERASIROX
Strength180MG
Dosage formGRANULE
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2021
Marketing statusRX

More from AUCTA

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

DEFERASIROX patent cliff — loss of exclusivity — | CliffBio